Open AccessPlacebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Author(s) -
Roy Fleischmann,
Joel M. Kremer,
John J. Cush,
Hendrik SchulzeKoops,
Carol A. Connell,
John Bradley,
David Gruben,
Gene V. Wallenstein,
Samuel H. Zwillich,
Keith S. Kanik
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1109071
Subject(s) - tofacitinib , medicine , rheumatoid arthritis , placebo , clinical trial , physical therapy , arthritis , alternative medicine , pathology
Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom